


Author's Accepted Manuscript

Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency

Andre Terzic MD, PhD, Atta Behfar MD, PhD



www.elsevier.com/locate/tcm

PII: S1050-1738(16)00021-9
DOI: <http://dx.doi.org/10.1016/j.tcm.2016.01.003>
Reference: TCM6240

To appear in: *trends in cardiovascular medicine*

Cite this article as: Andre Terzic MD, PhD, Atta Behfar MD, PhD, Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency, *trends in cardiovascular medicine*, <http://dx.doi.org/10.1016/j.tcm.2016.01.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

TCM-D-15-00152 Revised

STEM CELL THERAPY FOR HEART FAILURE: ENSURING REGENERATIVE PROFICIENCY

Andre Terzic, MD, PhD, and Atta Behfar, MD, PhD*

Center for Regenerative Medicine, Division of Cardiovascular Diseases, Department of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN

Short Title: Next-generation regenerative solution

*Corresponding author at: Mayo Clinic, Stable 5, 200 First Street SW, Rochester, MN, 55905; Tel. 507-2842747

E-mail address: terzic.andre@mayo.edu (A. Terzic).

Acknowledgments: Drs. Terzic and Behfar report research grants, administered by Mayo Clinic, from Marriott Foundation, Michael S. and Mary Sue Shannon Family, Russ and Kathy VanCleve Foundation, Leducq Fondation, Florida Heart Research Institute, Celyad, and National Institutes of Health in support of work in the laboratory. Drs. Terzic and Behfar are listed as co-inventors on patents US 20080019944 and US 20120100533.

ABSTRACT

Patient-derived stem cells enable promising regenerative strategies but display heterogeneous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytopreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.

Download English Version:

<https://daneshyari.com/en/article/6003634>

Download Persian Version:

<https://daneshyari.com/article/6003634>

[Daneshyari.com](https://daneshyari.com)